Vista Finance LLC Increases Stock Position in Medpace Holdings, Inc. $MEDP

Vista Finance LLC grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,158 shares of the company’s stock after acquiring an additional 45 shares during the quarter. Vista Finance LLC’s holdings in Medpace were worth $363,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Medpace during the 2nd quarter valued at about $2,216,000. Chevy Chase Trust Holdings LLC boosted its holdings in shares of Medpace by 1.5% during the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 15,131 shares of the company’s stock valued at $4,749,000 after acquiring an additional 219 shares during the last quarter. Oxbow Advisors LLC boosted its holdings in shares of Medpace by 3.6% during the 2nd quarter. Oxbow Advisors LLC now owns 9,188 shares of the company’s stock valued at $2,884,000 after acquiring an additional 323 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of Medpace by 4.8% during the 2nd quarter. Nordea Investment Management AB now owns 61,125 shares of the company’s stock valued at $19,067,000 after acquiring an additional 2,792 shares during the last quarter. Finally, Empirical Asset Management LLC boosted its holdings in shares of Medpace by 29.9% during the 2nd quarter. Empirical Asset Management LLC now owns 1,993 shares of the company’s stock valued at $626,000 after acquiring an additional 459 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Transactions at Medpace

In other news, CFO Kevin M. Brady sold 12,000 shares of the business’s stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the transaction, the chief financial officer owned 6,000 shares of the company’s stock, valued at approximately $2,725,380. The trade was a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 48,487 shares of the business’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the completion of the transaction, the chief executive officer directly owned 962,615 shares in the company, valued at $434,803,569.35. This trade represents a 4.80% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 161,266 shares of company stock valued at $74,111,427. 20.30% of the stock is owned by corporate insiders.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $528.07 on Friday. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $547.15. The company has a market capitalization of $14.84 billion, a P/E ratio of 39.26, a P/E/G ratio of 3.31 and a beta of 1.40. The firm’s 50 day simple moving average is $492.23 and its two-hundred day simple moving average is $382.32.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on MEDP shares. Cowen downgraded shares of Medpace from a “buy” rating to a “sell” rating in a report on Wednesday, July 23rd. Rothschild & Co Redburn downgraded shares of Medpace from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $342.00 to $474.00 in a report on Wednesday, September 3rd. William Blair reissued a “market perform” rating on shares of Medpace in a report on Wednesday, July 23rd. Rothschild Redb downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Finally, Jefferies Financial Group raised their price objective on shares of Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a report on Tuesday, September 9th. Two analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $430.60.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.